pazopanib has been researched along with Chordoma* in 2 studies
1 review(s) available for pazopanib and Chordoma
| Article | Year |
|---|---|
Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity. Topics: Adult; Aged; Carcinoma, Renal Cell; Chordoma; Female; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Skull Base Neoplasms; Sulfonamides | 2020 |
1 other study(ies) available for pazopanib and Chordoma
| Article | Year |
|---|---|
[A Case of Chordoma of the Sacrum Treated with Pazopanib].
A-70-year-old man with chordoma of the sacrum was treated with pazopanib (initially 400 mg/day, upto 800 mg/day). After 2 months of treatment, a significant tumor reduction was achieved and the patient was able to sit down easily. Therefore, the pazopanib therapy was continued. He had 14 months of progression-free survival. Topics: Aged; Angiogenesis Inhibitors; Biopsy; Chordoma; Humans; Indazoles; Male; Pyrimidines; Quality of Life; Sacrum; Spinal Neoplasms; Sulfonamides | 2016 |